Health News   Health Library   Health Topics   Healthy Living   HealthLink
Today's Headlines    Health Alerts    Health News Feature   
Future of Medicine    Health Observances    Product Recalls
Illnesses & Conditions    Drug Guide    FDA Drug Approvals    Complementary Medicine    Medical Tests   
Self-Help Resources    Medline Search
Allergies    Asthma    Back Pain    Cancer    Caregiver    Depression    Diabetes    Digestive Disorders
Heart Disease    Kidney Disease    Men's Health    Parenting    Pregnancy    Senior's Health
Stress    Stroke    Women's Health
Fitness    Nutrition    Mind & Body    Family & Home







Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

Fanapt Sanctioned for Schizophrenia


But FDA warns against off-label use

THURSDAY, May 7 (HealthDay News) -- A new pill to treat adults with schizophrenia has been approved by the U.S. Food and Drug Administration.

Fanapt (iloperidone), which belongs to the atypical antipsychotic class of drugs, is not approved for patients with dementia-related psychosis, United Press International reported.

The FDA ordered that Fanapt carry a boxed warning about the increased risk of death associated with off-label use of the drug to treat behavioral problems in patients with dementia-related psychosis.

Fanapt is made by Patheon Inc., in Ontario, Canada, for Vanda Pharmaceuticals Inc., of Rockville, Md., UPI reported.

More information

The FDA has more about this approval.
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay


Powered by Healthvision